{"id":"https://openalex.org/W4246716625","doi":"https://doi.org/10.1158/1538-7445.sabcs18-3909","title":"Abstract 3909: Potential antitumor effect of a pan-PI3K inhibitor ZSTK474 on human sarcoma cell lines","display_name":"Abstract 3909: Potential antitumor effect of a pan-PI3K inhibitor ZSTK474 on human sarcoma cell lines","alternate_titles":[],"publication_year":2019,"publication_date":"2019-07-01","ids":{"openalex":"https://openalex.org/W4246716625","doi":"https://doi.org/10.1158/1538-7445.sabcs18-3909"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.sabcs18-3909","doi":"https://doi.org/10.1158/1538-7445.sabcs18-3909","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.sabcs18-3909","pdf_url":null,"source":{"id":"https://openalex.org/S4306510252","display_name":"Experimental and Molecular Therapeutics","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Experimental and Molecular Therapeutics","raw_type":"proceedings-article"},"parent_works":[],"lineage":["https://openalex.org/W4246716625"],"child_works_count":0,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5003695970","display_name":"Shingo Dan","orcid":"https://orcid.org/0000-0002-0022-2725","observed_orcids":["https://orcid.org/0000-0002-0022-2725"]},"institutions":[{"id":"https://openalex.org/I42570316","display_name":"Japanese Foundation For Cancer Research","ror":"https://ror.org/00bv64a69","country_code":"JP","type":"nonprofit","lineage":["https://openalex.org/I42570316"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Shingo Dan","raw_affiliation_strings":["Japanese Fdn. for Cancer Research, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Japanese Fdn. for Cancer Research, Tokyo, Japan","institution_ids":["https://openalex.org/I42570316"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046357734","display_name":"Naomi Tamaki","orcid":"https://orcid.org/0009-0001-5341-0922","observed_orcids":["https://orcid.org/0009-0001-5341-0922"]},"institutions":[{"id":"https://openalex.org/I42570316","display_name":"Japanese Foundation For Cancer Research","ror":"https://ror.org/00bv64a69","country_code":"JP","type":"nonprofit","lineage":["https://openalex.org/I42570316"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Naomi Tamaki","raw_affiliation_strings":["Japanese Fdn. for Cancer Research, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Japanese Fdn. for Cancer Research, Tokyo, Japan","institution_ids":["https://openalex.org/I42570316"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056538575","display_name":"Nachi Namatame","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I42570316","display_name":"Japanese Foundation For Cancer Research","ror":"https://ror.org/00bv64a69","country_code":"JP","type":"nonprofit","lineage":["https://openalex.org/I42570316"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Nachi Namatame","raw_affiliation_strings":["Japanese Fdn. for Cancer Research, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Japanese Fdn. for Cancer Research, Tokyo, Japan","institution_ids":["https://openalex.org/I42570316"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009362679","display_name":"Yuya Yoshizawa","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I42570316","display_name":"Japanese Foundation For Cancer Research","ror":"https://ror.org/00bv64a69","country_code":"JP","type":"nonprofit","lineage":["https://openalex.org/I42570316"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Yuya Yoshizawa","raw_affiliation_strings":["Japanese Fdn. for Cancer Research, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Japanese Fdn. for Cancer Research, Tokyo, Japan","institution_ids":["https://openalex.org/I42570316"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5104140055","display_name":"Mutsumi Okamura","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I42570316","display_name":"Japanese Foundation For Cancer Research","ror":"https://ror.org/00bv64a69","country_code":"JP","type":"nonprofit","lineage":["https://openalex.org/I42570316"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Mutsumi Okamura","raw_affiliation_strings":["Japanese Fdn. for Cancer Research, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Japanese Fdn. for Cancer Research, Tokyo, Japan","institution_ids":["https://openalex.org/I42570316"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060700088","display_name":"Yumiko H. Nishimura","orcid":"https://orcid.org/0009-0001-9138-8463","observed_orcids":["https://orcid.org/0009-0001-9138-8463"]},"institutions":[{"id":"https://openalex.org/I42570316","display_name":"Japanese Foundation For Cancer Research","ror":"https://ror.org/00bv64a69","country_code":"JP","type":"nonprofit","lineage":["https://openalex.org/I42570316"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Yumiko Nishimura","raw_affiliation_strings":["Japanese Fdn. for Cancer Research, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Japanese Fdn. for Cancer Research, Tokyo, Japan","institution_ids":["https://openalex.org/I42570316"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103766974","display_name":"Kanami Yamazaki","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I42570316","display_name":"Japanese Foundation For Cancer Research","ror":"https://ror.org/00bv64a69","country_code":"JP","type":"nonprofit","lineage":["https://openalex.org/I42570316"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Kanami Yamazaki","raw_affiliation_strings":["Japanese Fdn. for Cancer Research, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Japanese Fdn. for Cancer Research, Tokyo, Japan","institution_ids":["https://openalex.org/I42570316"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5087295739","display_name":"Shin\u2010ichi Yaguchi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I42570316","display_name":"Japanese Foundation For Cancer Research","ror":"https://ror.org/00bv64a69","country_code":"JP","type":"nonprofit","lineage":["https://openalex.org/I42570316"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Shin-ichi Yaguchi","raw_affiliation_strings":["Japanese Fdn. for Cancer Research, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Japanese Fdn. for Cancer Research, Tokyo, Japan","institution_ids":["https://openalex.org/I42570316"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I42570316"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"3909","last_page":"3909"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.9404000043869019,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.9404000043869019,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10253","display_name":"Sarcoma Diagnosis and Treatment","score":0.054499998688697815,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11339","display_name":"Metabolism, Diabetes, and Cancer","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/zstk474","display_name":"ZSTK474","score":0.9890000224113464},{"id":"https://openalex.org/keywords/pan-pi3k-inhibitor","display_name":"pan-PI3K inhibitor","score":0.9200000166893005},{"id":"https://openalex.org/keywords/sarcoma","display_name":"sarcoma","score":0.8709999918937683},{"id":"https://openalex.org/keywords/pi3k-signaling","display_name":"PI3K signaling","score":0.7820000052452087},{"id":"https://openalex.org/keywords/antiproliferative-activity","display_name":"antiproliferative activity","score":0.902999997138977},{"id":"https://openalex.org/keywords/doxorubicin-resistance","display_name":"doxorubicin resistance","score":0.8820000290870667},{"id":"https://openalex.org/keywords/p-glycoprotein","display_name":"P-glycoprotein","score":0.9679999947547913},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":0.671999990940094},{"id":"https://openalex.org/keywords/ewing-sarcoma","display_name":"Ewing sarcoma","score":0.8899999856948853},{"id":"https://openalex.org/keywords/alveolar-rhabdomyosarcoma","display_name":"alveolar rhabdomyosarcoma","score":0.9710000157356262},{"id":"https://openalex.org/keywords/ewsr1-fli1-fusion","display_name":"EWSR1-FLI1 fusion","score":0.8399999737739563},{"id":"https://openalex.org/keywords/chromosomal-translocation","display_name":"chromosomal translocation","score":0.6169999837875366},{"id":"https://openalex.org/keywords/fibrosarcoma","display_name":"fibrosarcoma","score":0.6790000200271606},{"id":"https://openalex.org/keywords/uterine-sarcoma","display_name":"uterine sarcoma","score":0.9549999833106995}],"concepts":[{"id":"https://openalex.org/C2778256501","wikidata":"https://www.wikidata.org/wiki/Q223911","display_name":"Sarcoma","level":2,"score":0.47650519013404846},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.46649810671806335},{"id":"https://openalex.org/C81885089","wikidata":"https://www.wikidata.org/wiki/Q189082","display_name":"Cell culture","level":2,"score":0.4417880177497864},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.419822633266449},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.30187028646469116},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.2665995955467224},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.10330384969711304},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.04968762397766113}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.sabcs18-3909","doi":"https://doi.org/10.1158/1538-7445.sabcs18-3909","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.sabcs18-3909","pdf_url":null,"source":{"id":"https://openalex.org/S4306510252","display_name":"Experimental and Molecular Therapeutics","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Experimental and Molecular Therapeutics","raw_type":"proceedings-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2898036491","https://openalex.org/W2743529703","https://openalex.org/W2143945587","https://openalex.org/W4232463967","https://openalex.org/W1999404089","https://openalex.org/W2086030097","https://openalex.org/W1971742828","https://openalex.org/W1966307221","https://openalex.org/W4322421640","https://openalex.org/W1983020393"],"abstract_inverted_index":{"Phosphatidylinositol-3":[0],"kinase":[1,34],"(PI3K)":[2,35],"is":[3],"a":[4,22,31,52,78,143,154,194,198,253,259,266,393,426],"key":[5],"signaling":[6],"molecule":[7],"for":[8,25,182,397,442],"tumor":[9],"growth":[10,235],"and":[11,75,158,167,177,191,263,265,300,311,316],"survival,":[12],"thus":[13],"the":[14,45,73,119,160,165,183,239,287,372,439],"PI3K":[15,54,207,247],"pathway":[16],"has":[17,60],"been":[18,61],"thought":[19],"to":[20,51,113,126,205,234,274,284],"be":[21,392],"promising":[23,394],"target":[24],"cancer":[26,47],"therapy.":[27],"We":[28],"previously":[29,219],"identified":[30],"novel":[32],"phosphatidylinositol-3":[33],"inhibitor,":[36,55],"ZSTK474,":[37],"by":[38],"its":[39],"similarity":[40],"of":[41,80,90,105,115,121,130,136,147,156,162,172,185,246,278,286,306,352,375,425,438],"antiproliferative":[42,200,255],"profile":[43,201],"across":[44,164],"JFCR39":[46,222],"cell":[48,151,224,241,261,269,303,322,328,337,433],"line":[49,225,262,270],"panel":[50,145,166],"known":[53],"LY294002.":[56],"Since":[57],"then,":[58],"ZSTK474":[59,163,196,228,251,292,376,390,429],"evaluated":[62],"in":[63,69,72,101,133,232,237,297,354,377,383],"preclinical":[64],"models":[65],"as":[66,68,188,217,324,326],"well":[67,325],"clinical":[70,99,122],"trials":[71],"US":[74,85],"Japan":[76],"against":[77],"range":[79],"advanced":[81,108],"solid":[82],"tumors.":[83],"The":[84],"trial":[86,123],"revealed":[87],"that":[88,202,271,389],"three":[89],"four":[91],"sarcoma":[92,109,144,150,240,268,299,321,341,359,369,432],"patients":[93,106],"exhibited":[94,197,282],"stable":[95],"disease,":[96],"suggesting":[97,349],"possible":[98],"benefit":[100],"this":[102,131,139],"disease.":[103],"Treatment":[104],"with":[107,170,379],"remains":[110],"challenging":[111],"due":[112],"lack":[114],"effective":[116],"medicine.":[117],"Therefore":[118],"results":[120,387],"prompted":[124],"us":[125],"examine":[127],"antitumor":[128,373,423],"activity":[129,374],"compound":[132],"various":[134],"subtypes":[135,157],"sarcomas.":[137],"To":[138],"end,":[140],"we":[141,218],"developed":[142],"comprising":[146],"17":[148],"human":[149,368,431],"lines":[152,242,323,329,338,434],"from":[153,212,339],"variety":[155],"investigated":[159],"effect":[161,256,424],"compare":[168],"it":[169],"those":[171,400],"other":[173,206],"molecularly":[174],"targeted":[175],"agents":[176,181,289],"clinically":[178],"used":[179],"chemotherapeutic":[180,214,288],"treatment":[184],"sarcoma,":[186],"such":[187],"doxorubicin,":[189],"paclitaxel":[190],"gemcitabine.":[192],"As":[193],"result,":[195],"unique":[199],"was":[203],"similar":[204],"inhibitor":[208,428],"but":[209],"clearly":[210],"different":[211],"conventional":[213],"drugs":[215],"examined,":[216,243],"reported":[220],"using":[221,364],"carcinoma":[223,327],"panel.":[226],"Indeed,":[227],"inhibited":[229],"PI3K-downstream":[230],"pathways,":[231],"parallel":[233],"inhibition,":[236],"all":[238],"showing":[244],"proof-of-concept":[245],"inhibition.":[248],"Of":[249],"note,":[250],"exerted":[252],"potent":[254],"on":[257,430],"SW684,":[258],"fibrosarcoma":[260],"MES-SA/Dx5,":[264],"uterine":[267],"acquired":[272],"resistance":[273,283],"doxorubicin":[275],"via":[276],"overexpression":[277],"P-glycoprotein,":[279],"while":[280],"both":[281,305],"most":[285],"examined.":[290],"Moreover,":[291],"induced":[293],"extensive":[294],"apoptosis":[295,353],"selectively":[296],"Ewing\u2019s":[298],"alveolar":[301],"rhabdomyosarcoma":[302],"lines,":[304],"which":[307],"harbor":[308],"chromosomal":[309,356,403],"translocations":[310],"resulting":[312],"fusion":[313,344],"genes,":[314],"EWSR1-FLI1":[315],"PAX3-FOXO1,":[317],"respectively,":[318],"whereas":[319],"remaining":[320],"examined":[330],"so":[331],"far":[332],"hardly":[333],"underwent":[334,347],"apoptosis.":[335],"Additional":[336],"synovial":[340],"harboring":[342,401],"SS18-SSX1/2":[343],"gene":[345],"also":[346],"apoptosis,":[348],"preferential":[350],"induction":[351],"oncogenic":[355,402],"translocation":[357],"positive":[358],"cells.":[360,385],"Finally,":[361],"animal":[362],"experiments":[363],"nude":[365],"mice":[366],"bearing":[367],"xenograft":[370],"confirmed":[371],"vivo,":[378],"superior":[380],"efficacy":[381],"observed":[382],"translocation-positive":[384],"These":[386],"suggest":[388],"could":[391],"drug":[395],"candidate":[396],"sarcomas,":[398],"especially":[399],"translocation.Citation":[404],"Format:":[405],"Shingo":[406],"Dan,":[407],"Naomi":[408],"Tamaki,":[409],"Nachi":[410],"Namatame,":[411],"Yuya":[412],"Yoshizawa,":[413],"Mutsumi":[414],"Okamura,":[415],"Yumiko":[416],"Nishimura,":[417],"Kanami":[418],"Yamazaki,":[419],"Shin-ichi":[420],"Yaguchi.":[421],"Potential":[422],"pan-PI3K":[427],"[abstract].":[435],"In:":[436],"Proceedings":[437],"American":[440],"Association":[441],"Cancer":[443,457],"Research":[444],"Annual":[445],"Meeting":[446],"2019;":[447],"2019":[448],"Mar":[449],"29-Apr":[450],"3;":[451],"Atlanta,":[452],"GA.":[453],"Philadelphia":[454],"(PA):":[455],"AACR;":[456],"Res":[458],"2019;79(13":[459],"Suppl):Abstract":[460],"nr":[461],"3909.":[462]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W4246716625","counts_by_year":[],"updated_date":"2026-11-13T13:42:25.865203","created_date":"2022-05-12T00:00:00"}
